To read EPA's February 1, 2013, response, click here. To read the committee's December 12, 2012, letter, click here.
Excerpt: By its inaction, HRSA essentially turned a blind eye to entities who no longer should have been participating in the 340B program, allowing them to improperly reap the benefits of deeply discounted 340B drugs. Only last year did HRSA finally begin to ensure that participants continued to be eligible. … Maintaining the integrity of the 340B program is of the upmost importance, and we trust that you share our concerns.
To read the letter, click here.
To read the letter, click here. To read the NRC's February 19, 2013, response, click here.
To read the Food and Drug Administration's Response, click here. To read the initial letter to HHS, click here
Excerpt: During the past month, we have heard from a number of concerned citizens, including parents, law enforcement officials, health care providers, state and local officials, and our colleagues in Congress, about the impending release of the non-tamper-resistant versions of these opioids. According to these concerned citizens, the release of the non-tamper-resistant versions will deal a significant setback to our nation’s ongoing struggle to stop prescription drug abuse.